Pluristem Therapeutics Inc. (PSTI) Receives $4.13 Consensus Target Price from Brokerages
Pluristem Therapeutics Inc. (NASDAQ:PSTI) has been given an average rating of “Buy” by the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $4.13.
A number of analysts have recently weighed in on the company. B. Riley assumed coverage on Pluristem Therapeutics in a research note on Tuesday, July 31st. They set a “buy” rating and a $4.50 price objective for the company. Zacks Investment Research raised Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 12th. Finally, ValuEngine raised Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd.
A hedge fund recently raised its stake in Pluristem Therapeutics stock. ARK Investment Management LLC increased its holdings in Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 87.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,436,501 shares of the biotechnology company’s stock after acquiring an additional 669,077 shares during the quarter. ARK Investment Management LLC owned about 1.30% of Pluristem Therapeutics worth $1,753,000 as of its most recent filing with the Securities & Exchange Commission. 3.63% of the stock is currently owned by hedge funds and other institutional investors.
About Pluristem Therapeutics
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
See Also: How to Invest in Marijuana Stocks
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.